It is made available under a CC-BY-NC-ND 4.0 International license .

| 1 | TITLE: Comparative evaluation of rapid isothermal amplification and antigen assays for |
|----|--|
| 2 | screening testing of SARS-CoV-2 |
| 3 | |
| 4 | AUTHORS: Nol Salcedo ^{1*} , Brena F. Sena ^{1*} , Xiying Qu ^{1a} , Bobby Brooke Herrera ^{1,2} |
| 5 | |
| 6 | AFFILITIONS: ¹ E25Bio, Inc., Cambridge, MA, USA |
| 7 | ² Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public |
| 8 | Health, Boston, MA, USA |
| 9 | ^a Current Address: Flagship Pioneering 75, Cambridge, MA 02139, USA |
| 10 | *Equal contribution |
| 11 | [#] Corresponding authors: BBH, <u>bbherrera@e25bio.com</u> |
| 12 | |
| 13 | |
| 14 | |
| 15 | |
| 16 | |
| 17 | |
| 18 | |
| 19 | |
| 20 | |
| 21 | |
| 22 | |
| 23 | |

It is made available under a CC-BY-NC-ND 4.0 International license .

24 ABSTRACT

Human transmission of SARS-CoV-2 and emergent variants of concern has 25 continued to occur globally, despite mass vaccination campaigns. Public health strategies 26 27 to reduce virus spread should therefore rely, in part, on frequent screening with rapid, inexpensive, and sensitive tests. We evaluated two digitally integrated rapid tests and 28 29 assessed their performance using stored nasal swab specimens collected from individuals with or without COVID-19. An isothermal amplification assay combined with a 30 lateral flow test had a limit of detection of 10 RNA copies per reaction, and a positive 31 32 percent agreement (PPA)/negative percent agreement (NPA) during the asymptomatic and symptomatic phases of 100%/100% and 95.83/100%, respectively. Comparatively, 33 34 an antigen-based lateral flow test, had a limit of detection of 30,000 copies, and a 35 PPA/NPA during the asymptomatic and symptomatic phases of 82.86%/98.68% and 91.67/100%, respectively. Both the isothermal amplification and antigen-based lateral 36 flow tests had optimized detection of SARS-CoV-2 during the peak period of transmission: 37 38 however, the antigen-based test had reduced sensitivity in clinical samples with gPCR Ct values greater than 29.8. Low-cost, high-throughput screening enabled by isothermal 39 40 amplification or antigen-based techniques have value for outbreak control.

- 41
- 42
- 43
- 44
- 45
- 46

It is made available under a CC-BY-NC-ND 4.0 International license .

47 INTRODUCTION

48

Alongside widespread vaccine campaigns, strategies continue to be implemented 49 to reduce the human transmission of severe acute respiratory syndrome coronavirus 2 50 51 (SARS-CoV-2) (1-4). Testing, in particular, has played an important role throughout the 52 coronavirus disease 2019 (COVID-19) pandemic in detecting the virus and emergent 53 variants of concern, enabling responses at the national, community, and individual levels (5, 6). However, most testing occurs in centralized settings that utilize quantitative 54 55 polymerase chain reaction (gPCR) assays (7). While these molecular techniques can 56 detect minute amounts of viral RNA and therefore most appropriate for clinical diagnosis, they cannot be scaled to meet demands for extensive public health surveillance or 57 frequent screening of individuals, especially in resource limited settings. Inexpensive, 58 accurate tests that can be self-administered or performed at the point-of-care, and provide 59 60 actionable results, will further facilitate outbreak suppression.

61 Diagnostic testing for COVID-19 focuses on establishing the presence or absence of SARS-CoV-2 in symptomatic or asymptomatic individuals (8). In general, healthcare 62 63 professionals collect respiratory specimens via nasopharyngeal swabs or use less invasive approaches such as anterior nares swabs or saliva collection (9, 10). The 64 65 respiratory specimens then are processed by centralized high-complexity laboratories 66 with specialized equipment using qPCR assays with results being reported within 24 to 48 hours. In some regions, bottlenecks in laboratory-based testing have led to turnaround 67 68 times exceeding several days, diminishing the efficacy of this approach to prevent 69 ongoing transmission.

It is made available under a CC-BY-NC-ND 4.0 International license .

70 Surveillance testing estimates the infection dynamics of SARS-CoV-2 in representative sample sets, with the primary goal to inform public health policy. 71 72 Molecular-based techniques that are highly sensitive and specific, and report gPCR cycle 73 thresholds (Ct) and viral loads, are typically used for surveillance testing (11-13). An 74 emerging approach involves surveillance of SARS-CoV-2 via wastewater monitoring 75 using qPCR assays (14, 15). While surveillance testing is performed in centralized settings, the resulting information can be used to monitor epidemic trajectory in specific 76 communities and allow for real-time evaluation and/or implementation of mitigation 77 78 programs.

Identification of individuals who are likely infectious with screening testing is one
of the most effective, but underused, strategies to limit the ongoing transmission of SARSCoV-2 (16). In approximately 20-40% of COVID-19 cases, the infection remains
asymptomatic, and symptomatic disease is preceded by a pre-symptomatic incubation
period (17). Yet, pre-symptomatic and asymptomatic cases contribute significantly to
SARS-CoV-2 spread, challenging our ability to contain outbreaks (17).

Breaks in transmission chains can be most effectively achieved when screening testing is applied frequently and serially using self-administered rapid tests (18-20). Antigen-based tests, which utilize combinations of monoclonal antibodies and nanoparticles to detect viral proteins, do not require instruments or skilled operators; as of December 2021, 10 antigen tests for SARS-CoV-2 have been approved for at-home use in the United States (21). Although antigen tests have lower analytical sensitivity and specificity compared to qPCR assays, they have increased ability to detect SARS-CoV-2

It is made available under a CC-BY-NC-ND 4.0 International license .

92 during the acute phase of COVID-19 when an infected individual is most likely to transmit
93 the virus (22-24).

Moreover, isothermal amplification technologies offer the simplicity and speed of 94 95 antigen tests but have higher sensitivity and specificity (25-27). One of the most promising 96 isothermal amplification technologies is recombinase polymerase amplification (RPA) 97 (28, 29). In RPA, double stranded DNA denaturation and strand invasion is achieved by 98 a cocktail of enzymes including recombinases, single-stranded binding proteins, and DNA polymerases; typically, this occurs by multiple heat cycles in PCR (30). RPA has added 99 100 benefits over other isothermal amplification technologies (i.e., loop-mediated isothermal 101 amplification, LAMP or CRISPR) as reactions occur at ambient temperatures (37-42°C), 102 in shorter time periods, and results that can be visualized on a lateral flow test. One of 103 three isothermal amplification technologies currently available in the United States for at-104 home detection of SARS-CoV-2 utilizes reverse transcription RPA (RT-RPA), and has 105 been shown to detect the virus in nasal swab specimens with as low as twenty genome 106 copies (31, 32). Given their robust sensitivity and specificity, RT-RPA assays are 107 optimized to detect SARS-CoV-2 during the peak period of transmission in individuals 108 with pre-symptomatic, symptomatic, and/or asymptomatic infections (28, 33, 34).

Here, we performed a comparative evaluation of a RT-RPA assay and an antigen test. Using previously characterized nasal swab dilution specimens, we assessed the analytical sensitivity of the two tests. We show that the RT-RPA assay allows for detection of SARS-CoV-2 down to 10 RNA copies per reaction compared to folds higher with the antigen test. We then calculated the positive percent agreement (PPA, or sensitivity) and negative percent agreement (NPA, or specificity) using stored, unextracted nasal swab

It is made available under a CC-BY-NC-ND 4.0 International license .

specimens collected from individuals with or without COVID-19. We demonstrate that the RT-RPA assay has increased sensitivity in nasal swab specimens, particularly in qPCR Ct values greater than 29.8, regardless of if the sample was collected during the asymptomatic or symptomatic phases. Supporting the innovation, manufacturing, approval, and distribution of isothermal amplification screening tests will enable more effective control of infectious disease outbreaks.

121

122 MATERIALS AND METHODS

123

124 Clinical samples

The nasal swab dilution panel was provided by the non-profit PATH 125 126 (www.path.org). Nasal swab dilutions were prepared from human nasal swab eluate discards from suspected COVID-19 patients, collected within seven days post-symptoms 127 onset. A single swab eluate positive for SARS-CoV-2 by gPCR was diluted into a single 128 129 nasal eluate negative for SARS-CoV-2 by gPCR. For the dilution specimens with lower than 5,000 RNA copies, known quantities of RNA (ATCC, Manassas, VA) were spiked 130 131 into nasal eluates negative for SARS-CoV-2. Dilution specimens were de-identified, coded, and then aliquoted and frozen at -80°C. Aliquots were thawed and characterized 132 by qPCR as previously described (24). The primary studies under which the samples 133 134 were collected received ethical clearance from the PATH Institutional Review Board (IRB) (approval number 0004244). 135

Additionally, nasal swab specimens were collected from a cohort of suspected COVID-19 patients with or without symptoms at a point-of-care site (POC nasal swab

It is made available under a CC-BY-NC-ND 4.0 International license .

specimens); for individuals with symptoms, specimen were collected within the first 3 days
of symptoms onset. The nasal swabs were mixed in tubes containing 1X PBS
(MilliporeSigma, Burlington, MA). Aliquots were de-identified, coded, and then frozen at 80°C. The study under which the samples were collected received ethical clearance from
the Advarra, Inc. IRB (approval number Pro00044496).

143

144 qPCR

200 µl of the POC nasal swab specimens were used for extraction with the 145 146 MagMAX Viral/Pathogen II Nucleic Acid Isolation Kit (ThermoFisher Scientific, Waltham, 147 MA) on an epMotion 5075 (Eppendorf, Hamburg, Germany) liquid handler. Nucleic acids were eluted in 50 µl; 2 µl were used for gPCR confirmation using the GoTag Probe 1-148 Step RT-qPCR System (Promega, Madison, WI) on a QuantStudio 7 Flex Real-Time PCR 149 Instrument (ThermoFisher Scientific, Waltham, MA). The SARS-CoV-2 (2019-nCoV) 150 CDC gPCR Probe Assay was used to detect the human RNaseP gene and two viral 151 152 targets 2019-nCoV N1 and 2019-nCoV N2 (Integrated DNA Technologies, Coralville, IA). 153

154

155 RT-RPA assay

Prior to isothermal amplification testing, the nasal swab dilution specimens or POC
nasal swab specimens were lysed at 95°C using a heat block (Southern Labware,
Cumming, GA) for 3 minutes. Isothermal amplification reactions were conducted using
AmpliFast enzymes and buffer (E25Bio, Inc., Cambridge, MA), 1 µl RNase H (5U/µl;
ThermoFisher Scientific, Waltham, MA), 0.5 µl SuperScript IV RT (200 U/µl;

It is made available under a CC-BY-NC-ND 4.0 International license .

161 ThermoFisher Scientific, Waltham, MA), 0.5 µl of SARS-CoV-2 nucleocapsid (N) forward and reverse primers (300 nM final concentration), and 2 µl input template (nasal swab 162 163 dilution specimen or POC nasal swab specimen). This mix was activated by addition of 1 164 µl of magnesium acetate (14 nM final concentration), MilliporeSigma, Burlington, MA) followed by thorough mixing. Reactions were incubated at 38°C for 20 minutes. A 165 166 hybridization mix was prepared by combining 1 µI SARS-Cov-2 N biotinylated probe (0.167 nM final concentration) with 19 µl Tris pH 8 (10 mM). 20 µl of the hybridization mix 167 was added to each reaction, and samples were heated to 95°C for 3 minutes followed by 168 169 a cooling step at room temperature for 3 minutes. 40 µl of buffer (Pocket Diagnostic, York, 170 United Kingdom) were added to each reaction, then the mixture was applied to the PCRD nucleic acid lateral flow test (Pocket Diagnostic, York, United Kingdom) and allowed to 171 172 react for 10 minutes. Interactions of the immobilized test and control line antibodies with amplified nucleic acids and the nanoparticle conjugate produced visible bands, indicating 173 whether a test was positive or negative. 174

175

176 Antigen test

Rapid antigen tests (E25Bio, Inc., Cambridge, MA) contain a monoclonal antibody and a nanoparticle conjugate that detect SARS-CoV-2 N. 100 µl of the nasal swab dilution specimens or POC nasal swab specimens were applied to the antigen test and allowed to react for 15 minutes. Interactions of the immobilized test and control line antibodies with antigen and the nanoparticle conjugate produced visible bands, indicating whether a test was positive or negative.

It is made available under a CC-BY-NC-ND 4.0 International license .

184 Image analysis

Results from the isothermal amplification lateral flow tests and antigen-based 185 186 lateral flow tests were captured via the Passport App (currently available through Apple, 187 Inc.'s TestFlight; E25Bio, Inc., Cambridge, MA). The images were machine-read and processed to quantify test results. The average pixel intensity was quantified at the test 188 189 line, control line, and background areas. The background-subtracted test line signal was then normalized to the background-subtracted control line signal and the final test signal 190 was expressed as percent of control. The Passport App only stores images and 191 192 identifiable test results locally on the user's mobile device, and the individual can share 193 the results with whomever, whenever they choose.

194

195 Statistics

GraphPad Prism 9.0 (San Diego, CA) was used to analyze and report the performance of the isothermal amplification and antigen tests compared to qPCR. The sensitivity was defined as the fraction of total qPCR confirmed positive samples that are true positives according to the test. The specificity was defined as the fraction of total qPCR confirmed negative samples that are true negatives according to the test. Where appropriate, test signals were plotted using symbol and line graphs according to asymptomatic or symptomatic infection status and qPCR Ct thresholds.

203

204 Data availability

All relevant data have been included in the manuscript. We will provide any additional data upon request.

It is made available under a CC-BY-NC-ND 4.0 International license .

207

208 RESULTS

209 In the RT-RPA assay, viral RNA is first copied to cDNA by reverse transcriptase, 210 then degraded by RNase H. The cDNA product is amplified by RPA using a forward and 211 a FAM-labeled reverse pair of primers specific to the target sequence. The amplified 212 nucleic acid target is denatured and hybridized to a biotinylated probe. Dual FAM-labeled 213 and biotin-labeled products are then detected on a lateral flow test that contain 214 nanoparticles and detection molecules (i.e., anti-FAM antibody and streptavidin) specific 215 for FAM and biotin (Fig. 1A). In the antigen test, the interaction of antibodies and 216 nanoparticles with protein targets produces detectable bands (Fig. 1B). Both the RT-RPA 217 assay and the antigen test used in this study target SARS-CoV-2 N. To reduce errors in 218 user-based interpretation, we used a mobile phone application to machine read and 219 quantify the RT-RPA and antigen test results (Fig. 1C). Mobile phone image processing 220 allowed test users to obtain an objective analysis of their results, despite varied use 221 conditions, and share data in real-time.

We evaluated the analytical sensitivity of the RT-RPA assay and the antigen test using well-characterized nasal swab dilution specimens. The dilution specimens contained SARS-CoV-2 RNA copies ranging from 1 (Ct value 39.6) to 200,000 (Ct value 25.2). Consistent with expectations from qPCR, the RT-RPA assay yielded positive results with an input of 10 RNA copies per reaction (Ct value 37.3) (Fig. 2A-B). The antigen test reproducibly had detectable results with dilution specimens between 40,000 and 30,000 copies (Ct values 28.3 and 29.2, respectively) of SARS-CoV-2 (Fig. 2C-D).

It is made available under a CC-BY-NC-ND 4.0 International license .

The RT-RPA assay had a detection limit several orders of magnitude lower than the antigen test.

231 To further evaluate the RT-RPA and antigen tests, we compared their sensitivity 232 and specificity using stored, unextracted nasal swab specimens collected from individuals 233 with or without COVID-19. A total of 114 nasal swab specimens were negative and 59 234 were positive for SARS-CoV-2 by gPCR. Of the 114 negative specimens, 76 were collected from asymptomatic cases and 24 were collected from symptomatic cases. Of 235 236 the 59 SARS-CoV-2 positive specimens, 35 and 24 were collected from asymptomatic 237 or symptomatic cases, respectively. All 114 negative specimens were negative by the RT-238 RPA assay, regardless of symptoms, corresponding to a 100% specificity (Fig. 3, Table 239 1-2). Only 1 of 76 negative specimen from asymptomatic cases was positive by the 240 antigen test, corresponding to a 98.68% specificity (Fig. 3A, Table 1). All negative 241 specimens from 24 symptomatic cases were negative by the antigen test (100% 242 specificity) (Fig. 3B, Table 2). These results confirmed a low false positive rate for the RT-243 RPA assay and antigen test.

244 All 35 SARS-CoV-2 positive specimens from asymptomatic cases were positive by 245 the RT-RPA assay, corresponding to a 100% sensitivity (Fig. 3A, Table 1). Of the 24 246 positive specimens from the symptomatic phase, only 1 tested negative (95.83% sensitivity) (Fig. 3B, Table 2). In contrast, the antigen test detected 29 out of 35 (82.86% 247 248 sensitivity) asymptomatic SARS-CoV-2 positives and 22 out of 24 (91.67% sensitivity) 249 symptomatic positives (Fig. 3, Tables 1-2). Of note, the sensitivity of the antigen test 250 decreased significantly in Ct values greater than 30.1, while the sensitivity of the RT-RPA 251 assay was maintained (Fig. 3). Altogether, these results demonstrated that the true

It is made available under a CC-BY-NC-ND 4.0 International license .

252 positive rate of the RT-RPA assay was much higher than the antigen test especially during

the asymptomatic phase and particularly in specimens with higher Ct values.

254

255 DISCUSSION

One of the most promising strategies aimed at SARS-CoV-2 outbreak suppression is the screening of infectious individuals. This type of testing requires frequent and serial testing of large populations that can be self-administered or performed at the point-ofcare in high-transmission settings (i.e., schools, workplaces, etc.). The primary goal of screening testing is to achieve population-wide effects by breaking transmission chains through detection of cases, especially during the pre-symptomatic or asymptomatic phases.

263 Modeling studies have demonstrated that frequent rapid testing of large populations, even with varied test accuracies, can help achieve herd effects thereby 264 suppressing transmission of SARS-CoV-2 (18, 20, 35). In Slovakia, ~80% of the 265 266 population was screened for COVID-19 using antigen tests (36). In a 2-week period, 267 50,000 cases were identified, and along with other public health measures (i.e., wearing 268 masks, guarantining, etc.), the incidence was reduced by 82%. Further, at-home antigen testing was performed twice per week in a coworking environment in Cambridge, MA over 269 a 6-month period (19). In the case of a positive test, an individual would undergo a 10-270 271 day guarantine prior to returning to the workplace. Twice-weekly testing identified 15 272 individuals infected with SARS-CoV-2, with a test sensitivity of 96.2% on days 0-3 of 273 symptoms. This testing strategy allowed the activities of the coworking sites to continue

It is made available under a CC-BY-NC-ND 4.0 International license .

without pause. To our knowledge, screening testing using isothermal amplificationtechniques has not been extensively evaluated.

276 In this study, we performed a comparative evaluation of a RT-RPA assay and an 277 antigen test for SARS-CoV-2. We tested the analytical sensitivity using a nasal swab 278 dilution panel. The RT-RPA assay had a detection limit far lower than the antigen test. 279 We then analyzed the performance of the tests using qPCR characterized nasal swab specimens collected from individuals with or without COVID-19. The RT-RPA assay had 280 a high sensitivity (>95%) and specificity (100%) in specimens from asymptomatic or 281 282 symptomatic cases. In contrast, the sensitivity of the antigen test during the asymptomatic 283 phase was much lower at 82.86%, and especially with specimens that had Ct values 284 greater than 30. A likely explanation is that during the asymptomatic phase SARS-CoV-285 2 viremia has not peaked, resulting in reduced viral antigens in respiratory specimens. Additionally, Ct values >30 typically appear later in the course of SARS-CoV-2 infection 286 (i.e., 7 days after exposure), when virus is being eliminated by the immune system, 287 288 clearing antigen levels. In support of our hypotheses, the sensitivity of the antigen test 289 increased to >90% in nasal swab specimens collected from symptomatic cases within 3 290 days of symptoms onset.

Future work should broaden the evaluation of isothermal amplification and antigen assays to additional settings, sample types, and disease states (i.e., pre-symptomatic phase). Performance testing on prospectively collected samples will further corroborate preliminary findings. As the RT-RPA assay used in this study uses an inexpensive water bath and heat block, there is a need to for these types of assays to perform reactions with consumer-designed hardware that would allow for at-home or point-of-care testing.

It is made available under a CC-BY-NC-ND 4.0 International license .

Optimizing reaction mixes can also help reduce the temperatures and time required for test processing. Finally, the mobile phone application used in this study lessens user error by interpreting the results via pre-designed algorithms. Additional open-source, low-cost methods for data capture and reporting are warranted.

301 Public health screening requires rapid, inexpensive, and sensitive tests that can 302 be scaled for frequent and serial testing in large numbers. Antigen tests and upcoming 303 isothermal amplification assays fit these needs and could be scaled to millions of tests per day. Despite being shown to be highly effective at detecting infectious individuals. 304 305 there are only a handful of rapid tests currently available for self-administration or at-home 306 use in the United States. Even with approvals, these manufacturers have been unable to 307 meet the scale and demand, leaving individuals without access to these valuable inexpensive, rapid testing options. The support of manufacturing, rapid approval 308 processes, and distribution of screening tests will help control COVID-19 outbreaks. 309

310

311 ACKLOWLEDGEMENTS

We thank the staff of Cataldo Ambulance Service, notably David, Karen, and Pippa, for their help with patient recruitment and sample collection. We thank Professor Phyllis Kanki for critical reading of the manuscript.

315

316 COMPETING INTERESTS

This work was supported by E25Bio, Inc. NS, BFS, and BBH are employed by E25Bio, Inc., a company that develops rapid diagnostic tests for infectious diseases. At

It is made available under a CC-BY-NC-ND 4.0 International license .

- the time of the study, XQ was employed by E25Bio, Inc. BBH is an inventor on a U.S.
- 320 Provisional Patent Application (63/189,502).
- 321
- 322 REFERENCES
- 1. El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et
- al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N
- 325 Engl J Med. 2021;385(19):1774-85.
- 326 2. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety
- of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med.
 2021;385(12):1078-90.
- 329 3. Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B, et al.
- 330 Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J
- 331 Med. 2021;384(23):2187-201.
- 332 4. CDC. Mitigation measures for COVID-19 in households and markets in non-US
 333 low-resource settings. 2021.
- 5. CDC. Testing Strategies for SARS-CoV-2. 2021.
- Erster O, Beth-Din A, Asraf H, Levy V, Kabat A, Mannasse B, et al. SPECIFIC
 DETECTION OF SARS-COV-2 B.1.1.529 (OMICRON) VARIANT BY FOUR RT-qPCR
 DIFFERENTIAL ASSAYS. medRxiv. 2021:2021.12.07.21267293.
- 338 7. Binnicker MJ. Challenges and Controversies to Testing for COVID-19. J Clin
 339 Microbiol. 2020;58(11).
- Vandenberg O, Martiny D, Rochas O, van Belkum A, Kozlakidis Z. Considerations
 for diagnostic COVID-19 tests. Nat Rev Microbiol. 2021;19(3):171-83.

It is made available under a CC-BY-NC-ND 4.0 International license .

342 9. Bwire GM, Majigo MV, Njiro BJ, Mawazo A. Detection profile of SARS-CoV-2 using

343 RT-PCR in different types of clinical specimens: A systematic review and meta-analysis.

344 J Med Virol. 2021;93(2):719-25.

10. LeBlanc JJ, Heinstein C, MacDonald J, Pettipas J, Hatchette TF, Patriquin G. A
combined oropharyngeal/nares swab is a suitable alternative to nasopharyngeal swabs
for the detection of SARS-CoV-2. J Clin Virol. 2020;128:104442.

348 11. Kahn R, Kennedy-Shaffer L, Grad YH, Robins JM, Lipsitch M. Potential Biases
349 Arising From Epidemic Dynamics in Observational Seroprotection Studies. Am J
350 Epidemiol. 2021;190(2):328-35.

12. Hay JA, Kennedy-Shaffer L, Kanjilal S, Lennon NJ, Gabriel SB, Lipsitch M, et al.
Estimating epidemiologic dynamics from cross-sectional viral load distributions. Science.
2021;373(6552).

13. Tom MR, Mina MJ. To Interpret the SARS-CoV-2 Test, Consider the Cycle
Threshold Value. Clin Infect Dis. 2020;71(16):2252-4.

14. Peccia J, Zulli A, Brackney DE, Grubaugh ND, Kaplan EH, Casanovas-Massana
A, et al. Measurement of SARS-CoV-2 RNA in wastewater tracks community infection
dynamics. Nat Biotechnol. 2020;38(10):1164-7.

15. Randazzo W, Truchado P, Cuevas-Ferrando E, Simon P, Allende A, Sanchez G.
SARS-CoV-2 RNA in wastewater anticipated COVID-19 occurrence in a low prevalence
area. Water Res. 2020;181:115942.

362 16. Mina MJ, Parker R, Larremore DB. Rethinking Covid-19 Test Sensitivity - A
363 Strategy for Containment. N Engl J Med. 2020;383(22):e120.

It is made available under a CC-BY-NC-ND 4.0 International license .

364 17. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral
365 shedding and transmissibility of COVID-19. Nat Med. 2020;26(5):672-5.

18. Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, et al. Test
sensitivity is secondary to frequency and turnaround time for COVID-19 screening. Sci
Adv. 2021;7(1).

Harmon A, Chang C, Salcedo N, Sena B, Herrera BB, Bosch I, et al. Validation of
an At-Home Direct Antigen Rapid Test for COVID-19. JAMA Netw Open.
2021;4(8):e2126931.

Nash B, Badea A, Reddy A, Bosch M, Salcedo N, Gomez A. Validating and
Modeling the Impact of High-Frequency Rapid Antigen Screening on Covid-19 Spread
and Outcomes. J Clin Trials. 2021;11:483.

375 21. U.S. FDA. In Vitro Diagnostics EUAs - Antigen Diagnostic Tests for SARS-CoV-2.

276 22. Corman VM, Haage VC, Bleicker T, Schmidt ML, Muhlemann B, Zuchowski M, et

al. Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a

single-centre laboratory evaluation study. Lancet Microbe. 2021;2(7):e311-e9.

23. Pickering S, Batra R, Merrick B, Snell LB, Nebbia G, Douthwaite S, et al. Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation study. Lancet Microbe. 2021;2(9):e461-e71.

383 24. Salcedo N, Harmon A, Herrera BB. Pooling of Samples for SARS-CoV-2 Detection
384 Using a Rapid Antigen Test. Front Trop Dis. 2021;2:707865.

It is made available under a CC-BY-NC-ND 4.0 International license .

385 25. Ganguli A, Mostafa A, Berger J, Aydin MY, Sun F, Ramirez SAS, et al. Rapid
386 isothermal amplification and portable detection system for SARS-CoV-2. Proc Natl Acad
387 Sci U S A. 2020;117(37):22727-35.

26. Baek YH, Um J, Antigua KJC, Park JH, Kim Y, Oh S, et al. Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2. Emerg Microbes Infect. 2020;9(1):998-1007.

391 27. Rabe BA, Cepko C. SARS-CoV-2 detection using isothermal amplification and a
392 rapid, inexpensive protocol for sample inactivation and purification. Proc Natl Acad Sci U
393 S A. 2020;117(39):24450-8.

28. Qian J, Boswell SA, Chidley C, Lu ZX, Pettit ME, Gaudio BL, et al. An enhanced
isothermal amplification assay for viral detection. Nat Commun. 2020;11(1):5920.

396 29. Mancuso CP, Lu ZX, Qian J, Boswell SA, Springer M. A Semi-Quantitative
397 Isothermal Diagnostic Assay Utilizing Competitive Amplification. Anal Chem.
398 2021;93(27):9541-8.

399 30. Piepenburg O, Williams CH, Stemple DL, Armes NA. DNA detection using
400 recombination proteins. PLoS Biol. 2006;4(7):e204.

401 31. U.S. FDA. In Vitro Diagnostics EUAs - Molecular Diagnostic Tests for SARS-CoV-402 2.

32. Donato LJ, Trivedi VA, Stransky AM, Misra A, Pritt BS, Binnicker MJ, et al.
Evaluation of the Cue Health point-of-care COVID-19 (SARS-CoV-2 nucleic acid
amplification) test at a community drive through collection center. Diagn Microbiol Infect
Dis. 2021;100(1):115307.

It is made available under a CC-BY-NC-ND 4.0 International license .

| 407 | 33. | Ptasinska A, Whalley C, Bosworth A, Poxon C, Bryer C, Machin N, et al. Diagnostic |
|-----|--------|--|
| 408 | accura | acy of loop-mediated isothermal amplification coupled to nanopore sequencing |
| 409 | (LamF | PORE) for the detection of SARS-CoV-2 infection at scale in symptomatic and |
| 410 | asym | otomatic populations. Clin Microbiol Infect. 2021;27(9):1348 e1- e7. |
| 411 | 34. | Dong Y, Wu X, Li S, Lu R, Li Y, Wan Z, et al. Comparative evaluation of 19 reverse |
| 412 | transc | cription loop-mediated isothermal amplification assays for detection of SARS-CoV- |
| 413 | 2. Sci | Rep. 2021;11(1):2936. |
| 414 | 35. | Paltiel AD, Zheng A, Walensky RP. Assessment of SARS-CoV-2 Screening |
| 415 | Strate | gies to Permit the Safe Reopening of College Campuses in the United States. |
| 416 | JAMA | Netw Open. 2020;3(7):e2016818. |
| 417 | 36. | Pavelka M, Van-Zandvoort K, Abbott S, Sherratt K, Majdan M, group CC-w, et al. |
| 418 | The i | mpact of population-wide rapid antigen testing on SARS-CoV-2 prevalence in |
| 419 | Slova | kia. Science. 2021;372(6542):635-41. |
| 420 | | |
| 421 | | |
| 422 | | |
| 423 | | |
| 424 | | |
| 425 | | |
| 426 | | |
| 427 | | |
| 428 | | |
| 429 | | |

It is made available under a CC-BY-NC-ND 4.0 International license .

430 FIGURES



431

Figure 1. Schematic of RT-RPA assay versus antigen-based test. A) In RT-RTPA, viral 432 RNA is coped to cDNA by reverse transcriptase, then degraded by RNase H. Using a 433 434 forward and a FAM-labeled reverse pair of primers specific to a target sequence, the cDNA product is amplified by RPA, then denatured and hybridized to a biotinylated probe. 435 FAM-labeled and biotin-labeled products are detected on a lateral flow strip using 436 molecules specific for FAM and biotin and nanoparticles. B) In an antigen test, protein 437 targets are detected by a lateral flow strip using protein-specific antibodies and 438 439 nanoparticles. C) A mobile phone application was used to image capture, machine-read,

It is made available under a CC-BY-NC-ND 4.0 International license .

| 440 | and | quant | ify test results | s. The a | verage | e pixel intensity | / is quanti | fied a | t the | test line | e, co | ontrol |
|-----|-------|---------|------------------|----------|--------|-------------------|-------------|--------|--------|-----------|-------|--------|
| 441 | line, | and | background | areas. | The | background-si | ubtracted | test | line | signal | is | then |
| 442 | norm | nalizeo | d to the backg | round-s | ubtra | cted control line | e and expi | ressed | d at % | 6 of cor | trol | |
| 443 | | | | | | | | | | | | |
| 444 | | | | | | | | | | | | |
| 445 | | | | | | | | | | | | |
| 446 | | | | | | | | | | | | |
| 447 | | | | | | | | | | | | |
| 448 | | | | | | | | | | | | |
| 449 | | | | | | | | | | | | |
| 450 | | | | | | | | | | | | |
| 451 | | | | | | | | | | | | |
| 452 | | | | | | | | | | | | |
| 453 | | | | | | | | | | | | |
| 454 | | | | | | | | | | | | |
| 455 | | | | | | | | | | | | |
| 456 | | | | | | | | | | | | |
| 457 | | | | | | | | | | | | |
| 458 | | | | | | | | | | | | |
| 459 | | | | | | | | | | | | |
| 460 | | | | | | | | | | | | |
| 461 | | | | | | | | | | | | |
| 462 | | | | | | | | | | | | |

It is made available under a CC-BY-NC-ND 4.0 International license .



463

Figure 2. Analytical sensitivity of the RT-RPA assay and the antigen test using nasal 464 swab dilution specimens. A) Lateral flow strips for the RT-RPA reactions with dilution 465 specimens containing RNA copies ranging from 0-1,000. B) Plot from the RT-RPA assay 466 results quantified by the mobile phone application. The x-axis corresponds to dilutions 467 468 specimens with known input copies of SARS-CoV-2 RNA. The y-axis corresponds to background subtracted test signal normalized to the control line for each lateral flow strip. 469 470 Test results less that 10% of control are considered negative results, which is indicated 471 by the black dashed line. C) Lateral flow strips for the antigen tests with dilution specimens

It is made available under a CC-BY-NC-ND 4.0 International license .

| 472 | containing RNA copies ranging from 0-200,000 D) Plot from the antigen tests results |
|-----|---|
| 473 | quantified by the mobile phone application. The x-axis corresponds to dilutions specimens |
| 474 | with known input copies of SARS-CoV-2 RNA. The y-axis corresponds to background |
| 475 | subtracted test signal normalized to the control line for each lateral flow strip. Test results |
| 476 | less that 10% of control are considered negative results, which is indicated by the black |
| 477 | dashed line. |
| 478 | |
| 479 | |
| 480 | |
| 481 | |
| 482 | |
| 483 | |
| 484 | |
| 485 | |
| 486 | |
| 487 | |
| 488 | |
| 489 | |
| 490 | |
| 491 | |
| 492 | |
| 493 | |
| 494 | |

It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 3. Clinical performance of the RT-RPA assay and the antigen test using nasal swab specimens collected from individuals with or without COVID-19. A) Comparative evaluation of the RT-RPA assay (purple) and the antigen test (blue) using nasal swab specimens from asymptomatic cases. Comparative performance between the tests was plotted according to qPCR positive (Ct values between <20 to <40) and negative results. B) Comparative evaluation of the RT-RPA assay (purple) and the antigen test (blue) using nasal swab specimens from symptomatic cases. Comparative performance between the tests was plotted according to qPCR positive (Ct values between <20 to <40) and negative results.

It is made available under a CC-BY-NC-ND 4.0 International license .

512 TABLES

- Table 1. Comparative performance of the RT-RPA assay and the antigen test against
- 515 qPCR in asymptomatic cases.

| Asymptomatic Phase | | | | | | | | | | |
|--------------------|-------|------|----|-------|-----|---------|--------|---------|--|--|
| | | | | | | | | | | |
| | | qP | CR | | | | 95% CI | | | |
| | | + | | Total | PPA | 100.00% | 90.00% | 100.00% | | |
| | + | 35 | 0 | 35 | NPA | 100.00% | 95.26% | 100.00% | | |
| KI-KFA | | 0 | 76 | 76 | PPV | 100.00% | | | | |
| Total | | 35 | 76 | 111 | NPV | 100.00% | | | | |
| | | | | | | | | | | |
| | | qPCR | | | | | 95% CI | | | |
| | | + | | Total | PPA | 82.86% | 66.35% | 93.44% | | |
| Antigon | + | 29 | 1 | 30 | NPA | 98.68% | 92.89% | 99.97% | | |
| Anugen | - | 6 | 75 | 81 | PPV | 96.67% | 80.45% | 99.51% | | |
| | Total | 35 | 76 | 111 | NPV | 92.59% | 85.78% | 96.28% | | |

It is made available under a CC-BY-NC-ND 4.0 International license .

- 529 Table 2. Comparative performance of the RT-RPA assay and the antigen test against
- 530 qPCR in symptomatic cases.

| Symptomatic Phase | | | | | | | | | | |
|-------------------|-------|------|----|-------|------------|---------|--------|---------|--|--|
| | | | | | | | | | | |
| | | qPCR | | | | | 95% CI | | | |
| | | + | | Total | PPA | 95.83% | 78.88% | 99.89% | | |
| | + | 23 | 0 | 23 | NPA | 100.00% | 90.75% | 100.00% | | |
| KI-KFA | - | 1 | 38 | 39 | PPV | 100.00% | | | | |
| Total | | 24 | 38 | 62 | NPV 97.44% | | 84.80% | 99.62% | | |
| | | | | | | | | | | |
| | | qPCR | | | | | 95% CI | | | |
| | | + | | Total | PPA | 91.67% | 73.00% | 98.97% | | |
| Antigon | + | 22 | 0 | 22 | NPA | 100.00% | 90.75% | 100.00% | | |
| Anagen | - | 2 | 38 | 40 | PPV | 100.00% | | | | |
| | Total | 24 | 38 | 62 | NPV | 95.00% | 83.45% | 98.62% | | |